Cystadrops®
Cysteamine 0.37% · ophthalmic solution
Misc.
Approved uses
Corneal cystine crystal deposits in cystinosis
1 drop in each eye 4 times daily during waking hours; discard bottle 7 days after first opening
Corneal crystal score falls about 4.6 points over 90 days of four-times-daily dosing.
Contraindications
None.
Ophthalmic solution 0.37% (3.8 mg/mL cysteamine), 5 mL in a 10 mL amber glass bottle, with a separate dropper applicator
Cystine-depleting agent: converts cystine to cysteine and to cysteine-cysteamine mixed disulfides, reducing corneal cystine crystal accumulation. Systemic exposure following ophthalmic administration is expected to be negligible compared to oral administration, because the total daily ophthalmic dose is less than 4% of the recommended oral daily dose.
Warnings & Precautions
- Benign intracranial hypertension: Reported with oral cysteamine and resolved with added diuretic therapy; every reported case with the ophthalmic route was in a patient concurrently on the oral drug.
- Soft contact lenses: Benzalkonium chloride may be absorbed by soft lenses; avoid contact, remove lenses before instillation, and reinsert 15 minutes after.
- Dropper contamination: Do not touch the tip to the eyelids, surrounding areas, or any surface; keep the bottle tightly closed when not in use.
- In-use stability: Solution is only stable 7 days after first opening; discard at 7 days even if medication remains.
Common Side Effects
The most common adverse reactions (10% or greater) reported during clinical trials were eye pain, blurred vision, eye irritation, ocular hyperemia, instillation site discomfort, eye pruritus, increased lacrimation, and ocular deposits. That list contains no systemic reactions, and the total daily ophthalmic dose is less than 4% of the recommended oral daily dose.
Pregnancy: No adequate and well-controlled studies of ophthalmic cysteamine in pregnant women; oral cysteamine through organogenesis in rats was teratogenic at 240 to 960 times the recommended human ophthalmic dose based on body surface area (intrauterine death, cleft palate, kyphosis, ventricular septal defects, microcephaly, exencephaly, growth deficits). Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: No data on human milk, the breastfed infant, or milk production; cysteamine is present in the milk of orally dosed lactating rats. It is not known whether measurable levels of cysteamine would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CYSTADROPS and any potential adverse effects on the breastfed child.
Safety and effectiveness established in pediatric patients.